A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials.
Robustness, a long-recognized property of living systems, allows function in the face of uncertainty while fragility, i.e., extreme sensitivity, can potentially lead to catastrophic failure following seemingly innocuous perturbations. Carlson and Doyle hypothesized that highly-evolved networks, e.g....
Guardado en:
Autores principales: | Satyaprakash Nayak, Saniya Salim, Deyan Luan, Michael Zai, Jeffrey D Varner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6015800c8a134424b3c02cacc2536f44 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Revealing the role of molecular rigidity on the fragility evolution of glass-forming liquids
por: C. Yildirim, et al.
Publicado: (2016) -
Potential bias in ophthalmic pharmaceutical clinical trials
por: Paul Varner
Publicado: (2008) -
On clinical trial fragility due to patients lost to follow up
por: Benjamin R. Baer, et al.
Publicado: (2021) -
Fragility Index and Fragility Quotient in Randomized Controlled Trials on Corticosteroids in ARDS Due to COVID-19 and Non-COVID-19 Etiology
por: Maria Vargas, et al.
Publicado: (2021) -
Rett Syndrome and Fragile X Syndrome: Different Etiology With Common Molecular Dysfunctions
por: Snow Bach, et al.
Publicado: (2021)